方法：回顾性临床研究。纳入2019-01/2020-12于我院确诊的nARMD 1型MNV伴fPED患者48例48眼，根据治疗药物分为康柏西普组(26例26眼)和雷珠单抗组(22例22眼)，均采用3+PRN的治疗方案。随访12mo，观察两组患者最佳矫正视力(BCVA)，并采用光相干断层扫描(OCT)测量黄斑中心凹厚度(CFT)、视网膜色素上皮脱离(PED)的消退程度(高度、面积、体积)。

结果：两组患者治疗前BCVA、CFT及PED高度、面积和体积均无显著差异(P>0.05)。治疗(首次玻璃体内注射)后3、6、12mo两组患者PED高度均较治疗前显著改善(P<0.05)，但PED面积和体积均无显著改善(P>0.05)。治疗后两组患者BCVA较治疗前均无显著改善(P>0.05)。治疗后3、6、12mo康柏西普组患者CFT均较治疗前显著改善(P<0.05)，雷珠单抗组仅在治疗后3mo较治疗前显著改善(P<0.05)。治疗后3、6、12mo两组间BCVA、CFT及PED高度、面积和体积均无显著差异(P>0.05)。

结论：康柏西普和雷珠单抗治疗nARMD 1型MNV伴fPED均有较好疗效，能降低PED高度及CFT，稳定视力、PED面积和体积，而康柏西普减轻黄斑水肿的持续时间更为持久。

METHODS: Retrospective clinical study. From January 2019 to December 2020, 48 patients(48 eyes)of nARMD type 1 MNV patients with fPED diagnosed in our hospital were included and divided into conbercept group with 26 patients(26 eyes)and ranibizumab group with 22 patients(22 eyes)according to the drugs they received. All patients received treatment of 3+PRN. Followed up for 12mo, the best corrected visual acuity(BCVA)of the two groups was observed, and optical coherence tomography(OCT)was used to measure the macula foveal thickness(CFT)and the regression degree(height, area, volume)of retinal pigment epithelial detachment(PED).

RESULTS: There was no significant difference between two groups in BCVA, CFT and PED height, area and volume before treatment(P >0.05). The PED height of the two groups was significantly improved at 3, 6 and 12mo after the first intravitreal injection treatment compared with those before treatment(P<0.05). But the PED area and volume were not significantly improved(P>0.05). There was no significant improvement in BCVA between the two groups after treatment compared with those before treatment(P>0.05). The CFT of the conbercept group was significantly improved at 3, 6 and 12mo after treatment compared with those before treatment(P<0.05), and the ranibizumab group improved significantly only 3mo after treatment(P<0.05). There were no significant differences in BCVA, CFT, and PED height, area and volume between the two groups at 3, 6 and 12mo after treatment(P >0.05).

CONCLUSION: The conbercept and ranibizumab have good effects on type 1 MNV with fPED in nARMD, which can reduce the PED height and CFT, and stabilize the visual acuity, PED area and volume. However, conbercept can achieve longer reduction of macular edema.